- Home
- KYNB vs PSTV Comparison
KYNB vs PSTV Comparison
Compare KYNB & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KYNB | PSTV |
|---|---|---|
| Founded | 1993 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.9M | 27.9M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | KYNB | PSTV |
|---|---|---|
| Price | $6.91 | $6.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $55.00 |
| AVG Volume (30 Days) | 6.5K | ★ 252.6K |
| Earning Date | 05-04-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.61 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,213,000.00 |
| Revenue This Year | N/A | $13.20 |
| Revenue Next Year | N/A | $261.48 |
| P/E Ratio | $0.15 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.32 | $0.13 |
| 52 Week High | $9.58 | $8.00 |
Technical Indicators
Market Signals| Indicator | KYNB | PSTV |
|---|---|---|
| Relative Strength Index (RSI) | 44.72 | 60.66 |
| Support Level | $6.67 | $0.37 |
| Resistance Level | $7.42 | $6.65 |
| Average True Range (ATR) | 0.17 | 0.59 |
| MACD | -0.02 | -0.25 |
| Stochastic Oscillator | 11.72 | 20.40 |
Price Performance
Historical ComparisonAbout KYNB Kyntra Bio Inc. Common Stock
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).